Meletios Athanasios  Dimopoulos
Meletios Athanasios Dimopoulos
Verified email at
Cited by
Cited by
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ...
The lancet oncology 15 (12), e538-e548, 2014
International uniform response criteria for multiple myeloma
BGM Durie, JL Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, ...
Leukemia 20 (9), 1467-1473, 2006
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
International Myeloma Working Group
British journal of haematology 121 (5), 749-757, 2003
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ...
The lancet oncology 17 (8), e328-e346, 2016
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
JF San Miguel, R Schlag, NK Khuageva, MA Dimopoulos, O Shpilberg, ...
New England Journal of Medicine 359 (9), 906-917, 2008
Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ...
Journal of clinical oncology 33 (26), 2863, 2015
Hematological findings and complications of COVID‐19
E Terpos, I Ntanasis‐Stathopoulos, I Elalamy, E Kastritis, TN Sergentanis, ...
American journal of hematology 95 (7), 834-847, 2020
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
M Dimopoulos, A Spencer, M Attal, HM Prince, JL Harousseau, ...
New England Journal of Medicine 357 (21), 2123-2132, 2007
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors
A Bamias, E Kastritis, C Bamia, LA Moulopoulos, I Melakopoulos, ...
J Clin Oncol 23 (34), 8580-7, 2005
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ...
New England Journal of Medicine 375 (14), 1319-1331, 2016
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ...
New England Journal of Medicine 372 (2), 142-152, 2015
Elotuzumab therapy for relapsed or refractory multiple myeloma
S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ...
New England Journal of Medicine 373 (7), 621-631, 2015
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
JR Berenson, A Lichtenstein, L Porter, MA Dimopoulos, R Bordoni, ...
New England Journal of Medicine 334 (8), 488-493, 1996
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
SV Rajkumar, JL Harousseau, B Durie, KC Anderson, M Dimopoulos, ...
Blood, The Journal of the American Society of Hematology 117 (18), 4691-4695, 2011
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
RG Owen, SP Treon, A Al-Katib, R Fonseca, PR Greipp, ML McMaster, ...
Seminars in oncology 30 (2), 110-115, 2003
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A Dispenzieri, R Kyle, G Merlini, JS Miguel, H Ludwig, R Hájek, ...
Leukemia 23 (2), 215-224, 2009
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and …
RA Kyle, BGM Durie, SV Rajkumar, O Landgren, J Bladé, G Merlini, ...
Leukemia 24 (6), 1121-1127, 2010
Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma
A Palumbo, SV Rajkumar, MA Dimopoulos, PG Richardson, J San Miguel, ...
Leukemia 22 (2), 414-423, 2008
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label …
J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ...
The lancet oncology 14 (11), 1055-1066, 2013
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149-157, 2012
The system can't perform the operation now. Try again later.
Articles 1–20